DOCSLIB.ORG

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-Cell Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Published OnlineFirst February 29, 2016; DOI: 10.1158/1078-0432.CCR-15-2296 Biology of Human Tumors Clinical Cancer Research Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma Zijun Y. Xu-Monette1, Qipan Deng2, Ganiraju C. Manyam3, Alexander Tzankov4, Ling Li1, Yi Xia1, Xiao-xiao Wang1, Dehui Zou1, Carlo Visco5, Karen Dybkær6, Jun Li3, Li Zhang3, Han Liang3, Santiago Montes-Moreno7, April Chiu8, Attilio Orazi9, Youli Zu10, Govind Bhagat11, Kristy L. Richards12, Eric D. Hsi13, William W.L. Choi14, J. Han van Krieken15, Jooryung Huh16, Maurilio Ponzoni17, Andres J.M. Ferreri17, Ben M. Parsons18, Michael B. Møller19, Sa A. Wang1, Roberto N. Miranda1, Miguel A. Piris7, Jane N. Winter20, L. Jeffrey Medeiros1, Yong Li2, and Ken H. Young1,21 Abstract Purpose: MYC is a critical driver oncogene in many cancers, and synonymous mutations). Most of the nonsynonymous muta- its deregulation in the forms of translocation and overexpression tions correlated with better survival outcomes; in contrast, T58 has been implicated in lymphomagenesis and progression of and F138 mutations (which were associated with MYC rear- diffuse large B-cell lymphoma (DLBCL). The MYC mutational rangements), as well as several mutations occurred at the 30 profile and its roles in DLBCL are unknown. This study aims to untranslated region, correlated with significantly worse sur- determine the spectrum of MYC mutations in a large group of vival outcomes. However, these mutations occurred infre- patients with DLBCL, and to evaluate the clinical significance quently (only in approximately 2% of DLBCL). A germline of MYC mutations in patients with DLBCL treated with rituxi- SNP encoding the Myc-N11S variant (observed in 6.5% of the mab, cyclophosphamide, doxorubicin, vincristine, and predni- study cohort) was associated with significantly better patient sone (R-CHOP) immunochemotherapy. survival, and resulted in reduced tumorigenecity in mouse Experimental Design: We identified MYC mutations in 750 xenografts. patients with DLBCL using Sanger sequencing and evaluated the Conclusions: Various types of MYC gene mutations are present prognostic significance in 602 R-CHOP–treated patients. in DLBCL and show different impact on Myc function and clinical Results: The frequency of MYC mutations was 33.3% at the outcomes. Unlike MYC gene translocations and overexpression, DNA level (mutations in either the coding sequence or the most MYC gene mutations may not have a role in driving untranslated regions) and 16.1% at the protein level (non- lymphomagenesis. Clin Cancer Res; 22(14); 3593–605. Ó2016 AACR. Introduction resulted from aberrant class-switch recombination during ger- MYC is a proto-oncogene encoding the Myc protein, a minal center (GC) reaction and leading to Myc overexpression, transcription factor critical for cell proliferation, metabolism, underlies the pathogenesis of Burkitt lymphoma, and the differentiation, apoptosis, microenvironment remodeling, and poorer prognosis of approximately 10% of diffuse large B-cell immune responses. MYC-IGH chromosomal rearrangement, lymphoma (DLBCL) associated with MYC translocation (1). 1Department of Hematopathology,The University of Texas MD Ander- University Hospital, Odense, Denmark. 20Feinberg School of Medicine, son Cancer Center, Houston, Texas. 2Department of Cancer Biology, Northwestern University, Chicago, Illinois. 21The University of Texas Cleveland Clinic, Cleveland, Ohio. 3Department of Bioinformatics School of Medicine, Graduate School of Biomedical Sciences, Hous- and Computational Biology, The University of Texas MD Anderson ton, Texas. Cancer Center, Houston, Texas. 4University Hospital, Basel, Switzer- Note: Supplementary data for this article are available at Clinical Cancer land. 5San Bortolo Hospital,Vicenza, Italy. 6Aarhus University Hospital, Aalborg, Denmark. 7Hospital Universitario Marques de Valdecilla, Research Online (http://clincancerres.aacrjournals.org/). Santander, Spain. 8Memorial Sloan-Kettering Cancer Center, New Z.Y. Xu-Monette and Q. Deng contributed equally to this article. York, New York. 9Weill Medical College of Cornell University, New 10 11 York, New York. The Methodist Hospital, Houston, Texas. Columbia Corresponding Authors: Ken H. Young, The University of Texas MD Anderson University Medical Center and New York Presbyterian Hospital, New 12 Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. Phone: York, New York. University of North Carolina School of Medicine, 713-745-2598; Fax: 713-792-7273; E-mail: [email protected]; Yong Li, Chapel Hill, North Carolina. 13Cleveland Clinic, Cleveland, Ohio. 14Uni- Cleveland Clinic, Cleveland, OH 44106. Phone: 216-372-6889; E-mail: [email protected] versity of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China. 15Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. 16Asan Medical Center, Ulsan University College of Med- doi: 10.1158/1078-0432.CCR-15-2296 icine, Seoul, Korea. 17San Raffaele H. Scientific Institute, Milan, Italy. 18Gundersen Lutheran Health System, La Crosse, Wisconsin. 19Odense Ó2016 American Association for Cancer Research. www.aacrjournals.org 3593 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst February 29, 2016; DOI: 10.1158/1078-0432.CCR-15-2296 Xu-Monette et al. mutations (absent in GC-derived follicular lymphoma, pre-GC Translational Relevance mantle-cell lymphoma, post-GC multiple myeloma, and MYC mutations in diffuse large B-cell lymphoma (DLBCL) VH-mutated chronic lymphocytic leukemia as well as normal are not as well studied as MYC translocations, another form tissues) in the 50UTR and CDS regions of the MYC gene of MYC genetic aberrations. This study fills this knowledge harbored by 12 (32%) of 37 patients with DLBCL; these gap by profiling MYC gene mutations and germline variations mutations were proposed to originate from aberrant somatic in a large group of patients with DLBCL and attempts to under- hypermutation processes during DLBCL lymphomagenesis stand their impact on Myc function and clinical outcomes. (25). Through next-generation sequencing, 6 of 111 DLBCL We found a wide range of single-nucleotide variations of biopsies were found to have MYC mutations (26). However, MYC genes in DLBCL which correlated with different clini- the clinical relevance of MYC mutationsinDLBCLhasnotbeen cal outcomes. Mutations known to have gain-of-functions addressed. implicated in the pathogenesis of Burkitt lymphoma by pre- To fill this knowledge gap, this study aims to profile the vious studies were not frequent in DLBCL, whereas most spectrum and frequency of MYC mutations in a large cohort of MYC mutations were associated with better clinical outcomes. patients with DLBCL, to study the functional consequences and to These results suggested that most MYC mutations in DLBCL evaluate the prognostic significance of these MYC mutations. were probably passenger mutations instead of driver muta- tions during lymphomagenesis. This study showed, for the Patients and Methods first time, the clinical significance of MYC mutations in DLBCL, and supported the oncogenic role of MYC. Patients The study cohort consists of 750 patients with de novo DLBCL between 2000 and 2010 according to the World Health Orga- nization classification criteria as a part of the International DLBCL R-CHOP Consortium Program. Patients with trans- Paradoxically, Myc overexpression is also a potent inducer of formed DLBCL, primary mediastinal, cutaneous, or central apoptosis through the modulation of both p53-dependent and nervous system large B-cell lymphomas, or human immunode- p53-independent pathways, including the activation of TP53, ficiency virus infection were excluded. Cell-of-origin classifica- ARF, CD95/FAS,andBAX, and the inhibition of BCL2, BCLX, tion by either gene expression profiling or immunohistochem- and CFLAR/FLIP (2). Therefore, in tumors, deregulation of MYC ical algorithms has been described previously (1, 28). Survival is often concomitant with other abnormalities (e.g., Bcl-2 over- analysis was performed for 602 patients treated with standard expression) that cooperate with Myc during tumor onset, rituximab, cyclophosphamide, doxorubicin, vincristine, and progression, and chemoresistance (3–5). prednisone (i.e., R-CHOP) chemotherapy whose follow-up data In addition to MYC rearrangement, MYC mutation is another were available, randomly divided into a training set (n ¼ 368) form of genetic abnormality found in Burkitt lymphoma. Mul- and a validation set (n ¼ 234). At last follow-up, 208 of the 602 tiple nonsynonymous mutations in the coding sequence (CDS) of patients had died. The rest (394) patients were censored and had the MYC gene have been found in approximately 40% to 70% of a median follow-up time of 54 months (range, 3–187 months). Burkitt lymphoma leading to a mutated Myc protein with amino This study was conducted in accordance with the Declaration of acid changes (6–9). These Myc mutations cluster in the Myc Helsinki and was approved either as minimal to no risk or as transactivation domain with hotspots in the Myc box I (MBI) exempt from review by the Institutional Review Boards of all motif (44-63aa; Fig. 1A), and have been proposed to have a role in participating centers. lymphomagenesis by enhancing the oncogenicity of Myc (9–12). The clinicopathologic features of the patients with or without Functional studies indicated that Myc T58 mutants had increased mutations
Recommended publications
  • Translational Resistance of Late Alphavirus Mrna to Eif2␣ Phosphorylation: a Strategy to Overcome the Antiviral Effect of Protein Kinase PKR

    Translational Resistance of Late Alphavirus Mrna to Eif2␣ Phosphorylation: a Strategy to Overcome the Antiviral Effect of Protein Kinase PKR

    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Translational resistance of late alphavirus mRNA to eIF2␣ phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR Iván Ventoso,1,3 Miguel Angel Sanz,2 Susana Molina,2 Juan José Berlanga,2 Luis Carrasco,2 and Mariano Esteban1 1Departamento de Biología Molecular y Celular, Centro Nacional de Biotecnología/CSIC, Cantoblanco, E-28049 Madrid, Spain; 2Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Facultad de Ciencias, Cantoblanco, E-28049 Madrid, Spain The double-stranded RNA-dependent protein kinase (PKR) is one of the four mammalian kinases that phosphorylates the translation initiation factor 2␣ in response to virus infection. This kinase is induced by interferon and activated by double-stranded RNA (dsRNA). Phosphorylation of eukaryotic initiation factor 2␣ (eIF2␣) blocks translation initiation of both cellular and viral mRNA, inhibiting virus replication. To counteract this effect, most viruses express inhibitors that prevent PKR activation in infected cells. Here we report that PKR is highly activated following infection with alphaviruses Sindbis (SV) and Semliki Forest virus (SFV), leading to the almost complete phosphorylation of eIF2␣. Notably, subgenomic SV 26S mRNA is translated efficiently in the presence of phosphorylated eIF2␣. This modification of eIF2 does not restrict viral replication; SV 26S mRNA initiates translation with canonical methionine in the presence of high levels of phosphorylated eIF2␣. Genetic and biochemical data showed a highly stable RNA hairpin loop located downstream of the AUG initiator codon that is necessary to provide translational resistance to eIF2␣ phosphorylation. This structure can stall the ribosomes on the correct site to initiate translation of SV 26S mRNA, thus bypassing the requirement for a functional eIF2.
  • PARSANA-DISSERTATION-2020.Pdf

    PARSANA-DISSERTATION-2020.Pdf

    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
  • Gene Expression Polarization

    Gene Expression Polarization

    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
  • IP6K1 Upregulates the Formation of Processing Bodies by Promoting Proteome Remodeling on the Mrna Cap

    IP6K1 Upregulates the Formation of Processing Bodies by Promoting Proteome Remodeling on the Mrna Cap

    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.199828; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. IP6K1 upregulates the formation of processing bodies by promoting proteome remodeling on the mRNA cap Akruti Shah1,2 and Rashna Bhandari1* 1Laboratory of Cell Signalling, Centre for DNA Fingerprinting and Diagnostics (CDFD), Inner Ring Road, Uppal, Hyderabad 500039, India. 2Graduate studies, Manipal Academy of Higher Education, Manipal 576104, India. *Correspondence to Rashna Bhandari; Email: [email protected] Running title: IP6K1 promotes mRNA turnover to induce P-bodies ORCID IDs Akruti Shah - 0000-0001-9557-4952 Rashna Bhandari - 0000-0003-3101-0204 This PDF file includes: Main Text Figures 1 to 6 Keywords mRNA decay/mRNA metabolism/P-bodies/translation suppression 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.13.199828; this version posted July 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Inositol hexakisphosphate kinases (IP6Ks) are ubiquitously expressed small molecule kinases that catalyze the conversion of the inositol phosphate IP6 to 5-IP7. IP6Ks have been reported to influence cellular functions by protein-protein interactions independent of their enzymatic activity.
  • Efficacy and Mechanistic Evaluation of Tic10, a Novel Antitumor Agent

    Efficacy and Mechanistic Evaluation of Tic10, a Novel Antitumor Agent

    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2012 Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Joshua Edward Allen University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Oncology Commons Recommended Citation Allen, Joshua Edward, "Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent" (2012). Publicly Accessible Penn Dissertations. 488. https://repository.upenn.edu/edissertations/488 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/488 For more information, please contact [email protected]. Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Abstract TNF-related apoptosis-inducing ligand (TRAIL; Apo2L) is an endogenous protein that selectively induces apoptosis in cancer cells and is a critical effector in the immune surveillance of cancer. Recombinant TRAIL and TRAIL-agonist antibodies are in clinical trials for the treatment of solid malignancies due to the cancer-specific cytotoxicity of TRAIL. Recombinant TRAIL has a short serum half-life and both recombinant TRAIL and TRAIL receptor agonist antibodies have a limited capacity to perfuse to tissue compartments such as the brain, limiting their efficacy in certain malignancies. To overcome such limitations, we searched for small molecules capable of inducing the TRAIL gene using a high throughput luciferase reporter gene assay. We selected TRAIL-inducing compound 10 (TIC10) for further study based on its induction of TRAIL at the cell surface and its promising therapeutic index. TIC10 is a potent, stable, and orally active antitumor agent that crosses the blood-brain barrier and transcriptionally induces TRAIL and TRAIL-mediated cell death in a p53-independent manner.
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
  • The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars

    The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars

    CORE Metadata, citation and similar papers at core.ac.uk Provided by UEF Electronic Publications The expression of the human apolipoprotein genes and their regulation by PPARs Juuso Uski M.Sc. Thesis Biochemistry Department of Biosciences University of Kuopio June 2008 Abstract The expression of the human apolipoprotein genes and their regulation by PPARs. UNIVERSITY OF KUOPIO, the Faculty of Natural and Environmental Sciences, Curriculum of Biochemistry USKI Juuso Oskari Thesis for Master of Science degree Supervisors Prof. Carsten Carlberg, Ph.D. Merja Heinäniemi, Ph.D. June 2008 Keywords: nuclear receptors; peroxisome proliferator-activated receptor; PPAR response element; apolipoprotein; lipid metabolism; high density lipoprotein; low density lipoprotein. Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood environment for processing and energy supply in liver and other organs. In this study, the genomic area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) using the in vitro data-based computer program. Several new putative REs were found in surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Those results provide new insights in the understanding of lipid metabolism and so many lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke.
  • Transcriptome Analyses of Rhesus Monkey Pre-Implantation Embryos Reveal A

    Transcriptome Analyses of Rhesus Monkey Pre-Implantation Embryos Reveal A

    Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Transcriptome analyses of rhesus monkey pre-implantation embryos reveal a reduced capacity for DNA double strand break (DSB) repair in primate oocytes and early embryos Xinyi Wang 1,3,4,5*, Denghui Liu 2,4*, Dajian He 1,3,4,5, Shengbao Suo 2,4, Xian Xia 2,4, Xiechao He1,3,6, Jing-Dong J. Han2#, Ping Zheng1,3,6# Running title: reduced DNA DSB repair in monkey early embryos Affiliations: 1 State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 2 Key Laboratory of Computational Biology, CAS Center for Excellence in Molecular Cell Science, Collaborative Innovation Center for Genetics and Developmental Biology, Chinese Academy of Sciences-Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China 3 Yunnan Key Laboratory of Animal Reproduction, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 4 University of Chinese Academy of Sciences, Beijing, China 5 Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China 6 Primate Research Center, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China * Xinyi Wang and Denghui Liu contributed equally to this work 1 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press # Correspondence: Jing-Dong J. Han, Email: [email protected]; Ping Zheng, Email: [email protected] Key words: rhesus monkey, pre-implantation embryo, DNA damage 2 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Pre-implantation embryogenesis encompasses several critical events including genome reprogramming, zygotic genome activation (ZGA) and cell fate commitment.
  • Coupling of Spliceosome Complexity to Intron Diversity

    Coupling of Spliceosome Complexity to Intron Diversity

    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.19.436190; this version posted March 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Coupling of spliceosome complexity to intron diversity Jade Sales-Lee1, Daniela S. Perry1, Bradley A. Bowser2, Jolene K. Diedrich3, Beiduo Rao1, Irene Beusch1, John R. Yates III3, Scott W. Roy4,6, and Hiten D. Madhani1,6,7 1Dept. of Biochemistry and Biophysics University of California – San Francisco San Francisco, CA 94158 2Dept. of Molecular and Cellular Biology University of California - Merced Merced, CA 95343 3Department of Molecular Medicine The Scripps Research Institute, La Jolla, CA 92037 4Dept. of Biology San Francisco State University San Francisco, CA 94132 5Chan-Zuckerberg Biohub San Francisco, CA 94158 6Corresponding authors: [email protected], [email protected] 7Lead Contact 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.19.436190; this version posted March 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. SUMMARY We determined that over 40 spliceosomal proteins are conserved between many fungal species and humans but were lost during the evolution of S. cerevisiae, an intron-poor yeast with unusually rigid splicing signals. We analyzed null mutations in a subset of these factors, most of which had not been investigated previously, in the intron-rich yeast Cryptococcus neoformans.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Novel LRPPRC Compound Heterozygous Mutation in a Child

    Novel LRPPRC Compound Heterozygous Mutation in a Child

    Piro et al. Italian Journal of Pediatrics (2020) 46:140 https://doi.org/10.1186/s13052-020-00903-7 CASE REPORT Open Access Novel LRPPRC compound heterozygous mutation in a child with early-onset Leigh syndrome French-Canadian type: case report of an Italian patient Ettore Piro1* , Gregorio Serra1, Vincenzo Antona1, Mario Giuffrè1, Elisa Giorgio2, Fabio Sirchia3, Ingrid Anne Mandy Schierz1, Alfredo Brusco2 and Giovanni Corsello1 Abstract Background: Mitochondrial diseases, also known as oxidative phosphorylation (OXPHOS) disorders, with a prevalence rate of 1:5000, are the most frequent inherited metabolic diseases. Leigh Syndrome French Canadian type (LSFC), is caused by mutations in the nuclear gene (2p16) leucine-rich pentatricopeptide repeat-containing (LRPPRC). It is an autosomal recessive neurogenetic OXPHOS disorder, phenotypically distinct from other types of Leigh syndrome, with a carrier frequency up to 1:23 and an incidence of 1:2063 in the Saguenay-Lac-St Jean region of Quebec. Recently, LSFC has also been reported outside the French-Canadian population. Patient presentation: We report a male Italian (Sicilian) child, born preterm at 28 + 6/7 weeks gestation, carrying a novel LRPPRC compound heterozygous mutation, with facial dysmorphisms, neonatal hypotonia, non-epileptic paroxysmal motor phenomena, and absent sucking-swallowing-breathing coordination requiring, at 4.5 months, a percutaneous endoscopic gastrostomy tube placement. At 5 months brain Magnetic Resonance Imagingshoweddiffusecortical atrophy, hypoplasia of corpus callosum, cerebellar vermis hypoplasia, and unfolded hippocampi. Both auditory and visual evoked potentials were pathological. In the following months Video EEG confirmed the persistence of sporadic non epileptic motor phenomena. No episode of metabolic decompensation, acidosis or ketosis, frequently observed in LSFC has been reported.
  • Nuclear Expression of a Group II Intron Is Consistent with Spliceosomal Intron Ancestry

    Nuclear Expression of a Group II Intron Is Consistent with Spliceosomal Intron Ancestry

    Downloaded from genesdev.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Nuclear expression of a group II intron is consistent with spliceosomal intron ancestry Venkata R. Chalamcharla, M. Joan Curcio, and Marlene Belfort1 Center for Medical Sciences, Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA; and School of Public Health, State University of New York at Albany, Albany, New York 12201, USA Group II introns are self-splicing RNAs found in eubacteria, archaea, and eukaryotic organelles. They are mechanistically similar to the metazoan nuclear spliceosomal introns; therefore, group II introns have been invoked as the progenitors of the eukaryotic pre-mRNA introns. However, the ability of group II introns to function outside of the bacteria-derived organelles is debatable, since they are not found in the nuclear genomes of eukaryotes. Here, we show that the Lactococcus lactis Ll.LtrB group II intron splices accurately and efficiently from different pre-mRNAs in a eukaryote, Saccharomyces cerevisiae. However, a pre-mRNA harboring a group II intron is spliced predominantly in the cytoplasm and is subject to nonsense-mediated mRNA decay (NMD), and the mature mRNA from which the group II intron is spliced is poorly translated. In contrast, a pre-mRNA bearing the Tetrahymena group I intron or the yeast spliceosomal ACT1 intron at the same location is not subject to NMD, and the mature mRNA is translated efficiently. Thus, a group II intron can splice from a nuclear transcript, but RNA instability and translation defects would have favored intron loss or evolution into protein-dependent spliceosomal introns, consistent with the bacterial group II intron ancestry hypothesis.